$551 Million is the total value of Aquilo Capital Management, LLC's 14 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR S&P BIOTECH ETF TRput | $125,710,000 | – | 1,000,000 | +100.0% | 22.83% | – |
| SPRO | Buy | SPERO THERAPEUTICS INC | $84,017,000 | +57.2% | 4,563,688 | +19.2% | 15.26% | +9.9% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $53,633,000 | +35.9% | 521,673 | +16.3% | 9.74% | -5.0% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $49,525,000 | -26.8% | 2,456,595 | +35.5% | 9.00% | -48.8% |
| QURE | Buy | UNIQURE NV | $42,238,000 | +18.5% | 1,319,513 | +14.0% | 7.67% | -17.2% |
| RGNX | Buy | REGENXBIO INC | $35,177,000 | +52.1% | 839,139 | +40.9% | 6.39% | +6.3% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS INC | $32,958,000 | -8.1% | 527,926 | +21.9% | 5.99% | -35.7% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS INC | $29,665,000 | +30.3% | 1,099,944 | +16.3% | 5.39% | -8.9% |
| ARVN | New | ARVINAS INC | $29,150,000 | – | 354,711 | +100.0% | 5.29% | – |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $22,969,000 | -12.6% | 3,155,082 | +17.4% | 4.17% | -38.9% |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $16,743,000 | +21.1% | 1,390,000 | +21.9% | 3.04% | -15.4% |
| PIRS | PIERIS PHARMACEUTICALS INC | $16,526,000 | +35.0% | 3,196,527 | 0.0% | 3.00% | -5.6% | |
| ARGX | Buy | ARGENX SEsponsored adr | $6,704,000 | +5.0% | 22,200 | +4.7% | 1.22% | -26.6% |
| GMAB | Buy | GENMAB A/Ssponsored ads | $5,572,000 | +13.7% | 127,500 | +6.2% | 1.01% | -20.5% |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -142,340 | -100.0% | -2.55% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -712,674 | -100.0% | -2.57% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -1,194,237 | -100.0% | -6.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.